How to buy Repare Therapeutics stock (RPTX)

Repare Therapeutics is a biotechnology business based in the US. Repare Therapeutics shares (RPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.35 – an increase of 7.14% over the previous week. Repare Therapeutics employs 179 staff and has a trailing 12-month revenue of around $66.5 million.

Our top picks for where to buy Repare Therapeutics stock

Buy Repare Therapeutics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Repare Therapeutics stock price (NASDAQ: RPTX)

Use our graph to track the performance of RPTX stocks over time.

Repare Therapeutics shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$1.35
52-week range	$1.23 - $8.49
50-day moving average more info button	$3.23
200-day moving average more info button	$3.55
Wall St. target price	$8.50
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-1.99

Is it a good time to buy Repare Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Repare Therapeutics price performance over time

Historical closes compared with the close of $1.35 from 2024-12-24

1 week (2024-12-19)	2.27%
1 month (2024-11-26)	-57.14%
3 months (2024-09-26)	-61.43%
6 months (2024-06-26)	-59.94%

1 year (2023-12-26)	-81.61%
2 years (2022-12-23)	-90.72%
3 years (2021-12-23)	22.15
5 years (2019-12-22)	N/A

Repare Therapeutics financials

Revenue TTM	$66.5 million
Gross profit TTM	$15.1 million
Return on assets TTM	-23.39%
Return on equity TTM	-41.17%
Profit margin	-126.34%
Book value	$4.12
Market Capitalization more info button	$53.6 million

TTM: trailing 12 months

Repare Therapeutics share dividends

We're not expecting Repare Therapeutics to pay a dividend over the next 12 months.

Repare Therapeutics share price volatility

Over the last 12 months, Repare Therapeutics's shares have ranged in value from as little as $1.225 up to $8.49. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Repare Therapeutics's is 0.713. This would suggest that Repare Therapeutics's shares are less volatile than average (for this exchange).

Repare Therapeutics overview

Repare Therapeutics Inc. , a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase I/Ib clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F.

Frequently asked questions

What percentage of Repare Therapeutics is owned by insiders or institutions?
Currently 0.953% of Repare Therapeutics shares are held by insiders and 83.734% by institutions. How many people work for Repare Therapeutics?
Latest data suggests 179 work at Repare Therapeutics. When does the fiscal year end for Repare Therapeutics?
Repare Therapeutics's fiscal year ends in December. Where is Repare Therapeutics based?
Repare Therapeutics's address is: 7171 Frederick-Banting, Building 2, Montreal, QC, Canada, H4S 1Z9 What is Repare Therapeutics's ISIN number?
Repare Therapeutics's international securities identification number is: US7602731025